simvastatin and niacin
simvastatin has been researched along with niacin in 114 studies
Research
Studies (114)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.88) | 18.7374 |
| 1990's | 10 (8.77) | 18.2507 |
| 2000's | 51 (44.74) | 29.6817 |
| 2010's | 52 (45.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Erkelens, DW | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML | 1 |
| Feher, MD; Knight, BL; Lant, AF; Mayne, PD; Patel, DD; Soutar, AK; Webb, JC | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Grundy, SM | 2 |
| Albers, J; Brown, BG; Chait, A; Cheung, M; DeAngelis, D; Dowdy, A; Fisher, LD; Frohlich, J; Heise, N; Zhao, XQ | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Sinzinger, H | 1 |
| Hoogerbrugge, N | 1 |
| Isles, CG; Paterson, JR | 1 |
| Albers, JJ; Brown, BG; Chait, A; Cheung, MC; Zhao, XQ | 1 |
| McKenney, JM | 2 |
| Albers, JJ; Brown, BG; Cheung, MC; Kennedy, H; Wolfbauer, G | 1 |
| Kris-Etherton, PM | 1 |
| Ivanov, V; Netke, S; Niedzwiecki, A; Rath, M; Roomi, W | 1 |
| Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ | 1 |
| Freedman, JE | 1 |
| SoRelle, R | 1 |
| Stein, EA | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Drown, DJ | 1 |
| Harman, SM; Hecht, HS | 1 |
| Brown, BG; Giovanni, A; Lichtenstein, AH; Matthan, NR; Schaefer, EJ | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Asztalos, BF; Batista, M; Brown, GB; Cox, CE; Dallal, GE; Horvath, KV; Morse, JS; Schaefer, EJ | 1 |
| Lipton, AM; Lutjohann, D; Moore, C; Svetlik, D; Vega, GL; Von Bergmann, K; Weiner, MF | 1 |
| Baskin, F; Fang, X; Hynan, LS; Moore, CB; Rosenberg, RN; Vega, GL; Weiner, M | 1 |
| Ito, MK; Pieper, JA; Talbert, RL | 1 |
| Bays, HE; McGovern, ME | 2 |
| Albers, JJ; Brown, BG; Chait, A; DeAngelis, D; Dowdy, AA; Frohlich, J; Heise, N; Morse, JS; Zhao, XQ | 1 |
| Dierkes, J; Luley, C; Westphal, S | 1 |
| McKenney, J | 1 |
| Creavin, T | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Reasner, CA | 1 |
| Elisaf, MS; Milionis, HJ | 1 |
| Bloomgarden, ZT | 1 |
| Borges, JL | 1 |
| Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX | 1 |
| Huang, CH; Lai, WT; Lin, TH; Sheu, SH; Su, HM; Voon, WC; Yen, HW | 1 |
| Chu, B; Hatsukami, TS; Phan, BA; Polissar, N; Yuan, C; Zhao, XQ | 1 |
| Bays, HE; Jones, PH; Kashyap, ML; Knopp, RH; McGovern, ME; McKenney, JM; Ruoff, GE | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Balcerak, M; Broncel, M; Chojnowska-Jezierska, J | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Thara, E; Towne, SP | 1 |
| Bays, H | 1 |
| Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE | 1 |
| Bajorunas, DR; Davidson, MH; Karas, RH; Kashyap, ML; Keller, LH; Knopp, RH | 1 |
| Bajorunas, DR; Ballantyne, CM; Davidson, MH; Karas, RH; Keller, LH; McKenney, J | 1 |
| Kaye, T | 1 |
| Curran, MP; Sanford, M | 1 |
| Kashyap, ML; Vo, AN | 1 |
| Arora, A; Khan, BV; Pandian, A; Sperling, LS | 1 |
| Airan-Javia, SL; Mohler, E; Reilly, MP; Tadesse, M; Wolf, RL; Wolfe, ML | 1 |
| Cziraky, MJ | 1 |
| Robinson, JG | 1 |
| Charland, SL; Malone, DC | 1 |
| Mitka, M | 2 |
| Cheung, BM; Tse, HF; Yiu, KH | 1 |
| Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE | 1 |
| Charles, MA; Ishida, B; Kane, JP; Malloy, MJ; Pan, J; Shilian, P; Wu, X | 1 |
| Ahmed, MH | 1 |
| Chen, J; Chopp, M; Cui, X; Lu, M; Roberts, C; Shehadah, A | 1 |
| Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS | 1 |
| Guan, T; Hong, M; Li, G; Tang, X; Tao, X; Zhang, L; Zhao, X | 1 |
| Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE | 1 |
| Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV | 1 |
| Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y | 1 |
| Lyseng-Williamson, KA | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Brown, BG; Cheung, MC; Dobiásová, M; Frohlich, J; Sedová, M | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Davies, GM; Krobot, KJ; Michailov, GV | 1 |
| Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN | 1 |
| Inamadugu, JK; Mullangi, R; Nallapati, IK; Pilli, NR; Rao, JV | 1 |
| Anderson, T; Boden, WE; Chaitman, BR; Desvignes-Nickens, P; Koprowicz, K; McBride, R; Probstfield, JL; Teo, K; Weintraub, W | 1 |
| Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L | 1 |
| Jiang, P; Padley, RJ; Thakker, KM; Toth, PP | 1 |
| Adewale, AJ; Fazio, S; Guyton, JR; Jensen, E; Shah, A; Tershakovec, AM; Tomassini, JE | 1 |
| Prasad, V; Vandross, A | 1 |
| Havekes, LM; Heemskerk, MM; Jukema, JW; Kühnast, S; Louwe, MC; Pieterman, EJ; Princen, HM; Rensen, PC; Smit, JW; van den Berg, SA; van der Hoorn, JW; van Klinken, JB | 1 |
| Cabré, A; Masana, L; Plana, N | 1 |
| Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS | 1 |
| Jin, R; Le, NA; Neff, DR; Tershakovec, AM; Tomassini, JE; Wilson, PW | 1 |
| Khera, AV; Patel, PJ; Rader, DJ; Reilly, MP | 1 |
| Albers, JJ; Kashyap, ML; Kwiterovich, PO; Marcovina, SM; O'Brien, KD; Robinson, JG; Slee, A; Xu, P | 1 |
| Han, J; Liu, HC; Liu, M; Wang, XL; Wang, ZL; Yang, M; Zhang, D; Zhang, YN | 1 |
| Ballantyne, CM; Brunner, G; Chen, C; Dong, JF; Hoogeveen, RC; Kougias, P; Kumar, A; Lin, PH; Lumsden, AB; Morrisett, JD; Murray, T; Nambi, V; Negi, SI; Sun, W; Taylor, A; Virani, SS; Yang, EY | 1 |
| Han, J; Liu, HC; Liu, M; Wang, XL; Yang, M; Zhang, D; Zhang, LN; Zhang, YN | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Chen, E; Farnier, M; Johnson-Levonas, AO; McCrary Sisk, C; Mitchel, YB | 1 |
| Amigó, N; Ascaso, JF; Blanco-Vaca, F; Cabré, A; Correig, X; Girona, J; Heras, M; Julve, J; Martínez-Hervás, S; Masana, L; Palomer, X; Plana, N; Quesada, H; Real, JT; Vázquez-Carrera, M | 1 |
| Asif, A; Boden, WE; de Boer, IH; Ix, JH; Kalil, RS; Mathew, RO; Shi, X; Wang, JH | 1 |
| Amigó, N; Blanco Vaca, F; Correig, X; Escolà-Gil, JC; Heras, M; Mallol, R; Martínez-Hervás, S; Masana, L; Plana, N; Yanes, Ó | 1 |
| Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A | 1 |
| Alahmad, S; Elfatatry, HM; Hammad, SF; Mabrouk, MM; Mansour, FR | 1 |
| Armitage, J; Baigent, C; Collins, R; Haynes, R; Hill, MR; Hopewell, JC; Landray, M; Marcovina, S; Offer, A; Parish, S; Pedersen, TR; Valdes-Marquez, E | 1 |
Reviews
25 review(s) available for simvastatin and niacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Niacin; Simvastatin | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Supplements; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Triglycerides | 2000 |
Lipid management: tools for getting to the goal.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Drug Therapy, Combination; Humans; Hypercholesterolemia; Life Style; Niacin; Practice Guidelines as Topic; Simvastatin; United States | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin | 2004 |
New perspectives on the use of niacin in the treatment of lipid disorders.
Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Simvastatin | 2004 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin | 2007 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Do statins reduce events in patients with metabolic syndrome?
Topics: C-Reactive Protein; Cholesterol, LDL; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metabolic Syndrome; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2008 |
Safety of niacin and simvastatin combination therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin; Transaminases | 2008 |
Niacin extended-release/simvastatin.
Topics: Animals; Clinical Trials as Topic; Drug Combinations; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Simvastatin; Vitamins | 2008 |
Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
Topics: Animals; Cholesterol; Clinical Trials as Topic; Coronary Disease; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Risk Factors; Simvastatin; Triglycerides | 2008 |
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Topics: Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Patient Compliance; Simvastatin; Treatment Outcome | 2008 |
The impact of residual CVD risk in the managed care setting.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Managed Care Programs; Models, Economic; Niacin; Risk Factors; Simvastatin | 2009 |
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Topics: Aged; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin; Treatment Outcome | 2009 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Topics: Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Niacin; Simvastatin | 2010 |
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Niacin; Simvastatin | 2010 |
Trials
44 trial(s) available for simvastatin and niacin
| Article | Year |
|---|---|
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.
Topics: Adult; Aged; Antioxidants; Ascorbic Acid; beta Carotene; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Supplements; Drug Interactions; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Particle Size; Selenium; Simvastatin; Vitamin E | 2001 |
Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Cardiovascular Diseases; Carrier Proteins; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Membrane Proteins; Middle Aged; Niacin; Phospholipid Transfer Proteins; Simvastatin | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Coronary Stenosis; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Selenium; Simvastatin; Vitamin E | 2001 |
Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.
Topics: Antioxidants; Cholesterol; Constriction, Pathologic; Coronary Artery Disease; Desmosterol; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Niacin; Simvastatin; Sitosterols | 2003 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression; Electrophoresis, Agar Gel; Female; Humans; Lipids; Lipoproteins, HDL; Male; Middle Aged; Niacin; Particle Size; Radiography; Simvastatin; Treatment Outcome; Vitamins | 2003 |
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Brain; Cholesterol 24-Hydroxylase; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Simvastatin; Steroid Hydroxylases; Treatment Outcome | 2003 |
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Blood Platelets; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pravastatin; Protein Processing, Post-Translational; Simvastatin; Single-Blind Method | 2003 |
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Topics: Blood Glucose; Cholesterol, HDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Muscle, Skeletal; Niacin; Simvastatin | 2004 |
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Cross-Over Studies; Delayed-Action Preparations; Drug Carriers; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pyrroles; Reference Values; Simvastatin; Treatment Outcome | 2006 |
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
Topics: Aged; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2006 |
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Topics: Adult; Atorvastatin; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Niacin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin | 2008 |
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2008 |
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Topics: Administration, Oral; Adult; Aged; Cholesterol, HDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Tablets; Treatment Outcome | 2008 |
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.
Topics: Aged; Aged, 80 and over; Carotid Artery Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Retrospective Studies; Simvastatin; Treatment Outcome; Ultracentrifugation | 2009 |
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Niacin; Severity of Illness Index; Simvastatin; Tennessee; Time Factors; Treatment Outcome; Vitamin B Complex | 2010 |
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Simvastatin | 2011 |
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Niacin; Simvastatin; Treatment Outcome | 2010 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Niacin; Platelet Aggregation Inhibitors; Prospective Studies; Simvastatin; Vasodilator Agents | 2010 |
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cross-Over Studies; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Male; Niacin; Nicotinic Acids; Simvastatin; Tablets | 2011 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.
Topics: Antioxidants; Apolipoproteins B; Atherosclerosis; Cholesterol; Coronary Angiography; Coronary Stenosis; Drug Combinations; Esterification; Humans; Lipoproteins; Niacin; Particle Size; Simvastatin | 2011 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome | 2011 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2011 |
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscular Diseases; Niacin; Proportional Hazards Models; Simvastatin; Treatment Failure; Triglycerides | 2011 |
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Topics: Atorvastatin; Biomarkers; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; United States | 2012 |
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
Topics: Adolescent; Adult; Age of Onset; Aged; Azetidines; Delayed-Action Preparations; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Time Factors; Young Adult | 2012 |
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Death, Sudden, Cardiac; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Myocardial Reperfusion; Niacin; Simvastatin; Stroke | 2013 |
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
Topics: Aged; Atherosclerosis; Brain Ischemia; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Niacin; Simvastatin; Stroke; Thrombosis; Triglycerides | 2013 |
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Topics: Aged; Azetidines; Biomarkers; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Simvastatin; Time Factors; Treatment Outcome | 2013 |
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Hypoalphalipoproteinemias; Lipoprotein(a); Male; Metabolic Syndrome; Middle Aged; Niacin; Prospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2013 |
Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin.
Topics: Adolescent; Adult; Area Under Curve; Chromatography, Liquid; Drug Combinations; Female; Humans; Hypolipidemic Agents; Male; Niacin; Simvastatin; Tablets; Tandem Mass Spectrometry | 2014 |
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
Topics: Aged; Azetidines; Cholesterol; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Femoral Artery; Humans; Lipids; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Simvastatin | 2013 |
Gender differences in pharmacokinetics of a combination tablet of niacin extended-release/simvastatin in healthy Chinese volunteers.
Topics: Adult; Anticholesteremic Agents; Delayed-Action Preparations; Drug Combinations; Female; Healthy Volunteers; Humans; Male; Niacin; Sex Characteristics; Simvastatin; Tablets | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Topics: Adult; Aged; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Linear Models; Middle Aged; Niacin; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Metabolomics; Middle Aged; Niacin; Oxidants; Particle Size; Prospective Studies; Simvastatin; Spain; Time Factors; Treatment Outcome; Up-Regulation | 2015 |
Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Renal Insufficiency, Chronic; Secondary Prevention; Simvastatin; Triglycerides | 2015 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides | 2016 |
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Topics: Aged; Coronary Disease; Female; Humans; Hypolipidemic Agents; Indoles; Lipoprotein(a); Male; Middle Aged; Niacin; Protein Isoforms; Risk Factors; Simvastatin | 2018 |
Other Studies
46 other study(ies) available for simvastatin and niacin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin | 1990 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain | 1993 |
Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholesterol; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Pedigree; Polymorphism, Genetic; Probucol; Receptors, LDL; Simvastatin | 1993 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Antioxidant supplements and simvastatin-niacin therapy.
Topics: Antioxidants; Apolipoprotein A-I; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Simvastatin | 2001 |
Antioxidant versus lipid-altering therapy--some answers, more questions.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Stenosis; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Simvastatin | 2001 |
Niacin-simvastatin combination benefits patients with coronary artery disease.
Topics: Antioxidants; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Simvastatin | 2001 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
The effects of simvastatin-niacin and antioxidant therapy on HDL.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Outcome | 2002 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Niacin; Obesity; Risk Factors; Simvastatin | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Niaspan: new hope for heart patients.
Topics: Clinical Trials as Topic; Coronary Disease; Drug Combinations; Humans; Hypolipidemic Agents; Niacin; Simvastatin | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149:e17.).
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Pyrroles; Simvastatin | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Quinolines; Simvastatin; Triglycerides | 2005 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging.
Topics: Adult; Atherosclerosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Angiography; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Simvastatin | 2007 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Simcor: a niacin/simvastatin combination.
Topics: Cholesterol, HDL; Cholesterol, LDL; Costs and Cost Analysis; Drug Combinations; Drug Interactions; Dyslipidemias; Humans; Niacin; Simvastatin; Triglycerides | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin | 2008 |
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Practice Patterns, Physicians'; Risk Factors; Simvastatin; Treatment Outcome; Ultrasonography; United States; United States Food and Drug Administration | 2010 |
Ezetimibe and recent clinical trials: a look on the bright side.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Niacin; Placebos; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2010 |
Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome.
Topics: Amyloid beta-Protein Precursor; Animals; Axons; Brain; Brain Ischemia; Calcium-Binding Proteins; Delayed-Action Preparations; Disease Models, Animal; Drug Therapy, Combination; GPI-Linked Proteins; Infarction, Middle Cerebral Artery; Male; Microfilament Proteins; Microglia; Myelin Proteins; Neuroprotective Agents; Niacin; Nogo Receptor 1; Random Allocation; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Peptide; Simvastatin; Stroke; Treatment Outcome | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex | 2010 |
Preparation and evaluation of nicotinic acid sustained-release pellets combined with immediate release simvastatin.
Topics: Cellulose; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Excipients; Hypolipidemic Agents; Methacrylates; Microscopy, Electron, Scanning; Niacin; Polymers; Povidone; Simvastatin; Solubility | 2010 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Dyslipidemias; Female; Germany; Health Care Costs; Humans; Hypolipidemic Agents; Indoles; Life Expectancy; Male; Middle Aged; Models, Economic; Niacin; Risk Assessment; Secondary Prevention; Simvastatin | 2012 |
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin | 2011 |
Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Hypolipidemic Agents; Limit of Detection; Lovastatin; Male; Niacin; Simvastatin; Tandem Mass Spectrometry | 2012 |
Trial clouds use of niacin with a statin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure | 2011 |
Researchers still seek clinical benefit in raising levels of good cholesterol.
Topics: Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2012 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
Topics: Animals; Apolipoprotein E3; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Female; Gene Expression; Liver; Mice; Mice, Transgenic; Niacin; RNA, Messenger; Simvastatin; Triglycerides | 2013 |
HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe?
Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hypolipidemic Agents; Indoles; Niacin; Simvastatin | 2013 |
The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality.
Topics: Aged; Carotid Artery Diseases; Cholesterol, HDL; Clinical Trials as Topic; Female; Humans; Hypolipidemic Agents; Male; Niacin; Randomized Controlled Trials as Topic; Simvastatin | 2013 |
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorescent Dyes; Humans; Indoles; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Middle Aged; Niacin; Simvastatin; Surface Properties; Triglycerides | 2016 |
Development and Validation of Chemometric Spectrophotometric Methods for Simultaneous Determination of Simvastatin and Nicotinic Acid in Binary Combinations.
Topics: Chemistry, Pharmaceutical; Drug Combinations; Niacin; Reproducibility of Results; Simvastatin; Spectrophotometry, Ultraviolet | 2018 |